FOR IMMEDIATE RELEASE

First patient enrolled in Phase Ib-IIa clinical study
of Anfibatide for acute coronary syndrome (ACS)

Hong Kong, July 31, 2012—Lee’s Pharmaceutical Holdings Limited (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the first patient has been enrolled in a Phase Ib-IIa clinical trial of its first-in-class anti-platelet drug Declotana® (Anfibatide) in patients with acute coronary syndrome (ACS).

Declotana® is an antagonist of platelet 1b receptors being developed to prevent thrombosis in patients undergone PTCA and stenting as well as for treatment of ischemic heart diseases such as unstable angina. Our phase I trial evidenced that Anfibatide exhibits strong anti-platelet effects, excellent reversibility and low bleeding potential in human subjects. The current Phase II investigation of Anfibatide will define the optimal dosing strategy for safety and antithrombotic efficacy in acute coronary syndrome patients undergoing percutaneous coronary intervention and offer a preliminary, comparative assessment of the therapeutic benefits of Gp1b-IV-V complex antagonism.

This clinical trial is designed as a Ib-IIa multi-centers, randomized, double-blind, multi-dose, parallel group and placebo controlled clinical trial (clinicaltrial.gov registration No.: NCT01585259). It is led by Peking University first Hospital and participated by Chinese People's Liberation Army General Hospital (301 Hospital); Zhongshan Hospital affiliated to Fudan University; Tongji Hospital affiliated to Huazhong University of Science and Technology; General Hospital of Guangzhou Military Command of People's Liberation Army. Aim of the trial is to evaluate the safety, efficacy, tolerability of Anfibatide in non-ST-segment elevation myocardial infarction (NSTEMI) patients who will undergo PCI treatment after coronary angiography and provide theoretical information for Phase II and Phase III clinical trials of Anfibatide. The study plans to enroll a total of 90 patients assigned to four cohorts, 2 IU/60kg, 3 IU/60kg, 5 IU/60kg Anfibatide and placebo, respectively. The
FOR IMMEDIATE RELEASE

primary outcome measure of the current study is safety variables in NSTEMI patients, includes incidence of post operation complications, stent thrombosis formation, death and platelet count. The secondary outcome measures include the effect on bleeding time and pharmacokinetics of Anfibatide. The first patient of this study was enrolled on 31 July 2012 in Peking University first Hospital and the study is expected to last one year.

"We are thrilled of reaching this important milestone for Declotana® development in China. As a first-in-class drug, Declotana® is the first platelet Ib antagonist to complete human phase I study and to start Phase II study. This achievement attests the Group’s capability in new drug discovery and development and the R&D team’s drive to attain scientific excellence. We are looking forward to the successful completion of the study" stated Dr. Benjamin Li, the Chief Executive Officer of the Group.

About Declotana®

Declotana® (Anfibatide) is a new molecular entity discovered and developed by the Group from bench to bedside. It possesses the anti-platelet 1b receptors activity and is an effective anti-thrombosis agent in animal model. Animal studies have shown that intravenous injection of Anfibatide effectively abolishes the cyclic flow reduction in canine model of unstable agina with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. It represents a novel therapeutic mechanism and may advance the treatment of acute coronary syndrome and percutaneous coronary intervention. Declotana® has a quite favorable safety profile compared with other platelet inhibitors. It is expected that Declotana® could have an important role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of thrombosis in patients undergone PTCA and stenting. The Group has obtained patents in US and China for this product.

About Lee’s Pharmaceutical
FOR IMMEDIATE RELEASE
Lee’s Pharmaceutical Holdings Limited (“Lee’s”) is a research-based Hong Kong biopharmaceutical company with over 18 years operation in China’s pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with 20 international companies and currently has 13 products in the market place. Lee’s focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee’s development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee’s Pharmaceutical: Website: www.leespharm.com

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee’s financial condition and results of operations is detailed in Lee’s IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com